Liraglutide Injection, Solution
Product Images NDC 69097-920

Product Visual Gallery

This gallery contains 28 technical images submitted to the FDA as part of the official labeling for Liraglutide (NDC 69097-920). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cipla Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (3b5b3470 B3ac 4907 8e27 C31483bc5c8b 01)

Chemical structure diagram showing the amino acid sequence of liraglutide, highlighting specific residues including glutamic acid linked to a C-16 fatty acid (palmitoyl) and other amino acids such as histidine, alanine, glycine, and arginine. The sequence is arranged in a chain with labeled amino acids and a tail modification.*

FDA Label Image

Figure 2 (3b5b3470 B3ac 4907 8e27 C31483bc5c8b 02)

A line graph comparing Liraglutide Injection and placebo with ISR (pmol/kg/min) on the y-axis and Plasma Glucose (mg/dL) on the x-axis. The graph shows two curves representing insulin secretion rate changes relative to plasma glucose levels for Liraglutide Injection and placebo groups.*

FDA Label Image

Figure 3 (3b5b3470 B3ac 4907 8e27 C31483bc5c8b 03)

A line graph illustrating mean HbA1c (%) levels over 52 weeks comparing Glimepiride and Liraglutide Injection doses of 1.2 mg and 1.8 mg. The X-axis represents time in weeks, and the Y-axis shows mean HbA1c percentages between 6.5% and 9.0%. The graph includes annotations for statistical significance comparing Liraglutide doses to Glimepiride.*

FDA Label Image

Figure 4 (3b5b3470 B3ac 4907 8e27 C31483bc5c8b 04)

A line graph comparing mean HbA1c (%) over time (weeks) for Liraglutide Injection 1.2 mg, Liraglutide Injection 1.8 mg, and Sitagliptin 100 mg. The graph shows a decrease in HbA1c for both liraglutide doses compared to sitagliptin, with statistical significance noted (p<0.0001) for liraglutide versus sitagliptin. The y-axis represents mean HbA1c percentage, and the x-axis shows time in weeks, up to 26 weeks.*

FDA Label Image

Figure 5 (3b5b3470 B3ac 4907 8e27 C31483bc5c8b 05)

A Kaplan-Meier curve comparing the percentage of patients with an event over time (months) between Liraglutide Injection and placebo groups in a full analysis set. The graph includes patient numbers at risk at various time points and displays a hazard ratio (HR) of 0.87 with a 95% confidence interval of 0.78 to 0.97.*

FDA Label Image

Ifu Image (3b5b3470 B3ac 4907 8e27 C31483bc5c8b 06)

Illustration of the Liraglutide Injection Pen used for subcutaneous injection, showing parts labeled including pen cap, rubber stopper, cartridge tip, cartridge scale, cartridge, dose display, pointer, dose button, dose selector, and flow check symbol. Also shows example components of the needle: outer needle cap, inner needle cap, needle, and protective tab. Provides a helpline number for usage assistance.*

FDA Label Image

Image (3b5b3470 B3ac 4907 8e27 C31483bc5c8b 152 10)

An instructional illustration shows a hand holding a pen-like injection device with an arrow pointing away from the device tip, indicating the direction to pull or remove a cap or cover prior to use.*

FDA Label Image

Image (3b5b3470 B3ac 4907 8e27 C31483bc5c8b 152 11)

An instructional diagram showing a hand holding a syringe-like injection pen, with an arrow indicating the removal of a protective cap or cover from the pen. This image likely demonstrates part of the preparation process for subcutaneous injection of Liraglutide 6 mg/mL solution.*

FDA Label Image

Image (3b5b3470 B3ac 4907 8e27 C31483bc5c8b 152 12)

An instructional diagram illustrating a person holding a syringe for subcutaneous injection, with an arrow indicating the direction of injection into the skin.*

FDA Label Image

Image (3b5b3470 B3ac 4907 8e27 C31483bc5c8b 152 13)

An instructional illustration showing a hand pulling off a protective cap from the needle of a prefilled injection pen. The image highlights the step of preparing the Liraglutide injection device for subcutaneous administration.*

FDA Label Image

Image (3b5b3470 B3ac 4907 8e27 C31483bc5c8b 152 14)

An instructional illustration showing a close-up of a hand adjusting a dial on a liraglutide injection pen to select a dose. Below, three dose options are depicted with labels: 0.6 mg, 1.2 mg, and 1.8 mg, with the 0.6 mg dose highlighted as selected.*

FDA Label Image

Image (3b5b3470 B3ac 4907 8e27 C31483bc5c8b 152 15)

An instructional illustration showing recommended injection sites for Liraglutide 6 mg/mL subcutaneous injection. The diagram highlights the upper arms, stomach, and thigh as preferred areas for injection administration.*

FDA Label Image

Image (3b5b3470 B3ac 4907 8e27 C31483bc5c8b 152 16)

An instructional illustration showing a hand gripping a Liraglutide injection vial to prepare dosage. The image depicts the vial and highlights the dosage adjustment mechanism marked with numeric values, indicating how to set the desired injection amount in milligrams for subcutaneous administration.*

FDA Label Image

Image (3b5b3470 B3ac 4907 8e27 C31483bc5c8b 152 17)

An instructional diagram showing how to administer Liraglutide 6 mg/mL injection solution subcutaneously. It depicts a hand holding the injection pen, with an arrow indicating injection into the skin of the arm. Below is a clock symbol showing 6, likely referencing a wait time or dosage timing step.*

FDA Label Image

Image (3b5b3470 B3ac 4907 8e27 C31483bc5c8b 152 18)

An instructional illustration depicting a subcutaneous injection technique. The image shows a section of skin with a needle inserted vertically from above, indicated by a large blue upward-pointing arrow. The needle and syringe are positioned perpendicularly to the skin's surface, demonstrating the proper angle for injection.*

FDA Label Image

Image (3b5b3470 B3ac 4907 8e27 C31483bc5c8b 152 19)

An instructional diagram showing how to connect or attach parts of an injection pen. The image features a close-up of the pen's needle cap being removed or secured, indicated by a large blue arrow pointing leftward, demonstrating the proper handling step for the liraglutide injection solution pen device.*

FDA Label Image

Image (3b5b3470 B3ac 4907 8e27 C31483bc5c8b 152 2)

An instructional illustration showing a hand holding a liraglutide injection pen, with an arrow indicating the direction to pull or remove a part from the pen device, likely depicting the first step in preparing the liraglutide 6 mg/mL subcutaneous injection for use.*

FDA Label Image

Image (3b5b3470 B3ac 4907 8e27 C31483bc5c8b 152 20)

An instructional illustration showing a hand holding a syringe-like device with the thumb pulling back on the blue cap. The image likely demonstrates a step in preparing a subcutaneous injection.*

FDA Label Image

Image (3b5b3470 B3ac 4907 8e27 C31483bc5c8b 152 3)

An instructional illustration showing a hand gripping a syringe-like device labeled with measurement markings. The hand is lifting or twisting a purple component near the thumb, indicating a step in preparing the Liraglutide injection solution for subcutaneous administration.*

FDA Label Image

Image (3b5b3470 B3ac 4907 8e27 C31483bc5c8b 152 4)

An instructional illustration showing a hand holding a syringe with the needle inserted into the skin, indicating the subcutaneous injection technique with a blue arrow pointing away from the injection site.*

FDA Label Image

Image (3b5b3470 B3ac 4907 8e27 C31483bc5c8b 152 5)

An instructional illustration showing a hand pulling the needle cap off a prefilled syringe, indicated by a blue arrow pointing away from the syringe. This image aids in demonstrating how to prepare the injection device for use.*

FDA Label Image

Image (3b5b3470 B3ac 4907 8e27 C31483bc5c8b 152 6)

LIRAGLUTIDE 6 mg/mL injection, solution in a subcutaneous prefilled pen injector. The label displays the brand and generic name LIRAGLUTIDE and indicates the dosage strength as 6 mg/mL. The product is labeled by Cipla USA Inc. The packaging suggests a prescription drug form suitable for subcutaneous administration.*

FDA Label Image

Image (3b5b3470 B3ac 4907 8e27 C31483bc5c8b 152 7)

An instructional illustration showing a person peeling a protective strip from a strip labeled 'Flow check symbol selected.' The image highlights the flow check symbol on the strip, indicating its selection or verification.*

FDA Label Image

Image (3b5b3470 B3ac 4907 8e27 C31483bc5c8b 152 8)

An instructional diagram illustrating the proper technique for using a subcutaneous injection pen. It shows a hand holding and preparing the injection device, emphasizing a tapping motion to remove air bubbles from the solution before administration.*

FDA Label Image

Image (3b5b3470 B3ac 4907 8e27 C31483bc5c8b 152 9)

An instructional illustration showing a hand holding a LIRAGLUTIDE injection pen. It depicts adjusting the dose to 0 mg and an upward arrow indicating the direction of dose setting or injection preparation. A close-up inset shows the needle cap detail.*

FDA Label Image

Cartonpack3pens (3penscartonpacks)

Packaging label for Liraglutide Injection 18 mg/3 mL (6 mg/mL) solution for subcutaneous injection, distributed by Cipla USA Inc. The label includes images of the injection pen device and indicates boxes containing 3 pens each. It provides dosage strength and states Rx only with directions for use. The label also displays the product NDC 69097-920 and manufacturer details.*

FDA Label Image

2-pens-carton-pack (Carton 2 Pens)

Packaging label for Liraglutide Injection 18 mg/3 mL (6 mg/mL) solution for injection by Cipla USA Inc. The box contains 2 pens with subcutaneous injection delivery. The label includes dosage instructions, ingredients, manufacturer information, and barcode. The product NDC is 69097-920.*

FDA Label Image

Prefilledcontainerlabel (Label Container)

Liraglutide Injection 18 mg/3 mL (6 mg/mL) prefilled pen label by Cipla USA Inc. The label states the injection is for subcutaneous use only, includes storage instructions to refrigerate before first use and not to freeze, and notes it is for single patient use. The label also includes dosage details per pen and manufacturer information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.